SANGAMO THERAPEUTICS, INC (SGMOQ)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 90M 180M 270M Q2 '21: 137.7M Q3 '21: 108.5M Q4 '21: 110.7M Q1 '22: 112.7M Q2 '22: 114.2M Q3 '22: 112.1M Q4 '22: 111.3M Q1 '23: 241M Q2 '23: 218.5M Q3 '23: 201.4M Q4 '23: 176.2M Q1 '24: 18.8M Q2 '24: 12.3M Q3 '24: 52.3M Q4 '24: 57.8M Q1 '25: 63.8M Q2 '25: 81.7M Q3 '25: 32.9M Q4 '25: 39.6M Q1 '26: 34.6M Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-450M -300M -150M 0 150M 300M 450M Q2 '21: -142.1M Q3 '21: -186.9M Q4 '21: -183.3M Q1 '22: -182.3M Q2 '22: -179.3M Q3 '22: -185.8M Q4 '22: -201.3M Q1 '23: -138M Q2 '23: -215.8M Q3 '23: -267.3M Q4 '23: -274M Q1 '24: -343.6M Q2 '24: -257.1M Q3 '24: -140M Q4 '24: -104M Q1 '25: -82.1M Q2 '25: -62.8M Q3 '25: -109M Q4 '25: -121.2M Q1 '26: -123.6M Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

Net Income TTM

-450M -300M -150M 0 150M 300M 450M Q2 '21: -135.3M Q3 '21: -181.4M Q4 '21: -178.3M Q1 '22: -176.3M Q2 '22: -172.3M Q3 '22: -177.8M Q4 '22: -192.3M Q1 '23: -127.2M Q2 '23: -198.5M Q3 '23: -249.5M Q4 '23: -257.8M Q1 '24: -328.1M Q2 '24: -249.7M Q3 '24: -134.8M Q4 '24: -97.9M Q1 '25: -79.4M Q2 '25: -63.3M Q3 '25: -108.9M Q4 '25: -122.9M Q1 '26: -123.3M Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-270M -180M -90M 0 90M 180M 270M Q2 '21: -92.3M Q3 '21: -184.8M Q4 '21: -233.3M Q1 '22: -223.7M Q2 '22: -225.1M Q3 '22: -219.3M Q4 '22: -223.6M Q1 '23: -231M Q2 '23: -237.7M Q3 '23: -231.4M Q4 '23: -224.8M Q1 '24: -207.2M Q2 '24: -173.4M Q3 '24: -114.3M Q4 '24: -67.1M Q1 '25: -44.6M Q2 '25: -35.9M Q3 '25: -76.2M Q4 '25: -97.2M Q1 '26: -90.3M Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

Free Cash Flow TTM

-300M -200M -100M 0 100M 200M 300M Q2 '21: -115.6M Q3 '21: -209.3M Q4 '21: -256.5M Q1 '22: -241.8M Q2 '22: -241.4M Q3 '22: -234.8M Q4 '22: -243.8M Q1 '23: -258.5M Q2 '23: -265.3M Q3 '23: -257.3M Q4 '23: -246M Q1 '24: -218.2M Q2 '24: -178.8M Q3 '24: -117.1M Q4 '24: -67.4M Q1 '25: -44.9M Q2 '25: -36.2M Q3 '25: -76.4M Q4 '25: -97.3M Q1 '26: -90.5M Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 150M 300M 450M Q2 '20: 139M Q3 '20: 141.1M Q1 '21: 143.1M Q2 '21: 144M Q3 '21: 145.4M Q1 '22: 146.2M Q2 '22: 148.2M Q3 '22: 158M Q1 '23: 169.2M Q2 '23: 174.3M Q3 '23: 177.2M Q1 '24: 180.3M Q2 '24: 203.9M Q3 '24: 214.3M Q1 '25: 220.3M Q2 '25: 256.9M Q3 '25: 304.3M Q1 '26: 389.6M Q1 '21 Q1 '22 Q1 '23 Q1 '24 Q1 '25 Q1 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-2.10 -1.40 -0.70 0.00 0.70 1.40 2.10 Q2 '21: -0.95 Q3 '21: -1.27 Q4 '21: -1.23 Q1 '22: -1.21 Q2 '22: -1.17 Q3 '22: -1.18 Q4 '22: -1.25 Q1 '23: -0.83 Q2 '23: -1.20 Q3 '23: -1.45 Q4 '23: -1.47 Q1 '24: -1.86 Q2 '24: -1.38 Q3 '24: -0.75 Q4 '24: -0.53 Q1 '25: -0.40 Q2 '25: -0.30 Q3 '25: -0.45 Q4 '25: -0.44 Q1 '26: -0.38 Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q1 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.